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ABSTRACT 
Introduction- Gestational trophoblastic disease (GTD) forms a group of disorders spanning the 
conditions of complete and partial molar pregnancies through to the malignant conditions of 
invasive mole, choriocarcinoma and the very rare placental site trophoblastic tumour (PSIT). 
The World Health Organization classification divides Trophoblastic Disease into the Pre 
malignant condition which is Partial Hydratirfonn moles, Complete hydatidiform moles and 
malignant condition such as Persistant Trophoblastic Disease, Invasive Mole, Choriocarcinoma, 
Placental Site Tumours. Molar pregnancies can be subdivided into complete (CM) and partial 
moles (PM) based on genetic and histopathological features. GTD is a rare event in the Europe, 
with a calculated incidence of 1/714 live births. 
Objectives- To deteimine prevalence of different types of Gestational Trophoblastic diseases, 
assess the associated factors of malignant condition compared to pre malignant condition and to 
determine the outcome of the chemotherapy treatment for patient with GTD. 
Methodology - A retrospective review was conducted on all GTD cases over the 10 year period 
between January 2002 and December 2011. The diagnosis and staging was classified using FIGO 
anatomical staging (Appendix A) and had histopathological confirmation of the disease, data was 
compiled through a clinical research form for analysis and data analysis was carried out with 
SPSS version 22. 
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Results - Total of 123 cases were diagnosed with GTD within ten years span, there were 98 
cases of Benign form GTD and 25 cases of malignant form ofGTD. Among the benign form of 
GTD there were 53(43.1%) patients with partial hydatidiform mole and 45(36.6%) with 
complete hydatidiform mole diagnosed clinically and conformed by histopathological evaluation. 
Malignant form of GTD accounted for total of 25(20.3%) patients, among which persistant 
trophoblastic disease (PTD) consist of 22 patients (17.9%) and 3(2.4%) patients with 
choriocarcinoma Among the associated factors of malignant disease studied was age, ethnicity, 
pre treatment hCG level, parity, child birth spacing, size of the uterus, size of molar tissue, 
history of molar pregnancy, previous usage of oral contraceptive pills and presence of thecal 
luthean cyst. Among the risk factors, age was strongly associated with malignant GTD, it was 
noted that with increase in every year of age the odds of developing malignant GTD was 
increased by 5%, The outcome of two major treatment group namely MTX regimen and 
EMACO regimen was studied, total of 22 patients received MTX as a single agent therapy, all of 
them were diagnosed with PTD and 19 patients had FIGO stage I disease and one patient with 
FIGO stage II disease and each one patients in stage III and stage IV disease, the patients in 
stage II and Ill needed second line chemotherapy with Actinomycin D and achieved full 
recovery, 19 patients in stage I received single agent MTX and complete recovery was achieved 
in 12 patients resulting in a success rate of 63% when used a single agent in stage I disease. 
There were 7 patients with stage I disease who failed to achieve satisfactory response with MTX 
alone and eventually requiring Actinomycin D (37%) achieved complete recovery from the 
disease. In this study 3 patients received EMA-CO regime as treatment, all of them were 
diagnosed with choriocarcinoma, two patients had stage I disease. One of them had hysterectomy 
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done prior to treatment with EMA-CO and another received only EMA-CO after evacuation. 
Another one patient had stage IV disease with brain and liver metastasis, she was primarily 
started on EMA-CO and eventually succumbed to death. The remaining 2 patient had complete 
remission after treatment with EMA-CO, The success rate of EMA-CO in high risk patients at 
our center remains good as seen in previous studies. 
Conclusion - In this study the was no major changes in term of the epidemiology of the disease, 
it was well within the generally accepted prevalence for GTD. Perhaps the one of the most 
interesting finding in this study was the associated risk factors to develop malignant disease, in 
this study factors which had high association were age, high parity, and long interval of last child 
birth. Most patients had FIGO stage I disease, the response to single agent MTX treatment 
achieved an acceptable outcome, while the rest of the patients who received second line therapy 
also had a complete recovery. Patients who were in stage II and III had complete recovery with 
EMA-CO regime.MTX remains as our frrst line treatment in low risk patients while the usage of 
Actinomycin also proved beneficial in cases of resistant. For the patients in high risk category 
this study supports the use of EMA-CO. 
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ABSTRAK 
Pengenalan - Penyakit kandungan Mola atau lebih dikenali sebagai Gestational 
trophoblastic disease (GTD) adalah suatu kumpulan penyakit yang merangkumi kandugan 
molar penuh dan molar separa, hinggalah ke penyakit barah tropoblastik seperti invasif 
mol, khoriokarsinoma dan juga barah tropoblastik daripada uri.klasifikasi Pertubuhan 
kesihatan sedunia telah mebahagikan penyakit tropoblastik kepada dua kumpulan besar ia 
itu kumpulan Pra barah seperti hidatidifom mol separa dan hidatidifom mol penuh dan 
kumpulan penyakit barah seperti penyakit tropoblasti.k kekal, invasive 
mol,koriokarsinoma dan barah tropoblastik daripada uri.. Penyakit kandungan 
tropoblastik ialah suatu penyakit yang jarang dilihat di benua europa dengan kadar 
kejadian sekitar 1/714 kelahiran hidup. Terdapat bukti variasi etnik dalam kejadian GTD, 
dengan wanita dari Asia yang mempunyai kadar yang lebih tinggi berbanding dengan 
wanita bukan Asia (1/387 berbanding 1/752 kelahiran hidup). 
Objektif- Menentukan kelazimanjenis penyakit kandugan tropoblastik, menilai faktor-
faktor yang berkaitan dengan kumpulan penyakit tropoblastik barah berbanding dengan 
kumpulan penyakit pra barah dan menentukan hasil rawatan kemoterapi pada pesakit 
dengan penyakit tropoblastic barah yang dirawat di HUSM. 
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Kaedah- Satu kajian retrospektif telah dijalankan ke atas semua kes GTD bagi tempoh 
10 tahun antara J anuari 2002 dan Disember 2011 ,Diagnosis dan tahap penyakit 
diklasiflkasikan menggunakan klasiftkasi Tahap penyakit yang diiktiraf oleh FIGO 
(Lampiran A) dan mempunyai pengesahan histopatologi terhadap penyakit ini, data telah 
dipungut mengunakan borang pungutan data untuk tujuan analisis dan analisis data 
dijalankan dengan SPSS versi 22. 
Keputusan - Kajian ini meliputi keseluruhan pesakit dengan sebarang bentuk penyakit 
gestasi Tropoblastik sepanjang tempoh sepuluh tahun, dari Januari 2002 hingga Disember 
2011. Sejumlah 123 rekod pesakit telah dipilih, dikaji dan di analisis, terdapat 98 kes 
GTD berbentuk bukan barah dan 25 kes berbentuk barah. Antara kes berbentuk bukan 
barah daripada GTD adalah 53 (43.1 %) pesakit dengan hidatidifom mol separa dan 45 
(36.6%) dengan hidatiform lengkap yang disahkan secara klinikal dan penilaian 
histopatologi. Bentuk barah daripada GTD menyumbang sebanyak 25 (20.3%) pesakit, 
antaranya ialah penyakit tropoblastik kekal (PTD) terdiri daripada 22 pesakit (17.9%) dan 
3 (2.4%) pesakit dengan koriokarsinoma. Antara faktor-faktor yang berkaitan dengan 
penyakit GTD jenis barah yang dikaji adalah umur,kumpulan etnik, tahap hormon hCG 
sebelum rawatan, bilangan kelahiran, Jarak kelahiran, saiz rahim, saiz tisu molar, sejarah 
kehamilan molar, penggunaan pil perancang keluarga dan kewujudan lutheal cista. Antara 
faktor-faktor risiko dikaji, umur telah didapati berkait rapat dengan kejadian GTD jenis 
barah, berdasarkan keputusan kajian ia dilihat bahawa dengan peningkatan setiap tahun 
umur kemungkinan seseorang menghidap penyakit GTD jenis barah meningkat sebanyak 
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5%,. Hasil daripada dua kumpulan rawatan utama iaitu rejimen MTX dan rejimen 
EMACO telah dikaji, sejumlah 22 pesakit menerima MTX sebagai rawatan ejen tunggal, 
semua daripada mereka disahkan dengan PTD dan 19 pesakit mempunyai penyakit 
diperingkat tahap FIGO I dan seorang pesakit dengan tahap FIGO II penyakit dan seorang 
pesakit masing masing di peringkat III dan peringkat IV, pesakit dalam peringkat II dan 
III telah memerlukan kemoterapi pilihan kedua dengan Actinomycin D dan telah 
mencapai kadar pemulihan sepenuhnya, 19 pesakit di peringkat FIGO I telah menerima 
ejen nmggal MTX dan kadar pemulihan yang lengkap telah dicapai dalam 12 pesakit 
justeru menghasilkan dalam kadar kejayaan 63% apabila digunakan sebagai agen 
kemoterapi nmggal kepada pesakit di peringkat FIGO I. Terdapat 7 pesakit dengan 
penyakit peringkat FIGO I yang gagal mencapai kadar pemulihan yang memuaskan 
dengan MTX sahaja dan akhimya memerlukan Actinomycin D (37% ) dan telah pulih 
sepenuhnya. Dalam kajian ini 3 pesakit telah menerima rawatan rejimen EMA-CO, 
kesemua mereka telah disahkan dengan koriokarsinoma, dua pesakit mempunyai penyakit 
tahap FIGO I. Salah seorang daripada mereka telah mejalani histerektomi atau 
pembedahan mengeluarkan rahim sebelum rawatan dengan EMA-CO dan satu lagi hanya 
menerima EMA-CO selepas menjalani prosedur mencuci rahim. Seorang lagi pesakit 
mempunyai tahap penyakit IV yang telah merebak ke otak dan hati, beliau di rawat 
dengan rejimen EMA-CO dan akhimya telah meninggal dunia. Baki dua pesakit telah 
pulih sepenuhnya selepas rawatan dengan EMA-CO, Kadar kejayaan EMA-CO pada 
pesakit yang berisiko tinggi di pusat kami masih baik seperti yang dilihat dalam kajian-
kajian sebelum ini. 
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Kesimpulan- Dalam kajian ini tidak ada perubahan besar dari segi epidemiologi penyakit 
ini, ia masih berada pada kelaziman yang diterima umum untuk GTD. Salah satu daripada 
penemuan yang paling menarik dalam kajian ini adalah faktor-faktor risiko yang 
menyumbang kepada penyakit malignan GTD,berdasarkan kajian ini faktor yang berkait 
rapat termasuklah faktor usia,bilangan kelahiran anak yang ramai, danjarak kelahiran 
yang lama. Umur merupakan faktor utama yang menyumbang kepada penyakit malignan 
berbanding faktor-faktor risiko yang lain, Kebanyakan pesakit didapati berada di tahap 
penyakit FIGO peringkat I,rawatan dengan MTX telah mencapai hasil yang memuaskan, 
manakala pesakit lain yang menerima rawatan tahap kedua juga telah pulih sepenuhnya. 
Pesakit yang berada dalam FIGO peringkat II dan III telah pulih sepenulmya dengan 
rawatan rejimen EMACO.MTX kekal sebagai rawatan tahap pertama kami untuk pesakit 
berisiko rendah manakala penggunaan Actinomycin juga terbukti bermanfaat dalam 
rawatan untuk pesakit yang kebal kepada MTX . Bagi pesakit yang tergolong dalam 
kategori berisiko tinggi kajian ini menyokong penggunaan EMA-CO. 
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1.0 Introduction 
Gestational trophoblastic disease (GTD) forms a group of disorders spanning the conditions of 
complete and partial molar pregnancies to the malignant conditions such as invasive mole, 
choriocarcinoma and the very rare placental site trophoblastic tumor (PSTT). There are reports of 
neoplastic transformation of atypical placental site nodules to placental site trophoblastic tumor. 
The World Health Organization classification divides Trophoblastic Disease into the Pre 
malignant conditions which are Partial Hydatidiform moles, Complete hydatidiform moles and 
malignant conditions such as Persistent Trophoblastic Disease, Invasive Mole, 
Choriocarcinoma, Placental Site Tumours.(Altieri, Franceschi et al. 2003) 
Molar pregnancies can be subdivided into complete (CM) and partial moles (PM) based on 
genetic and histopathological features. Complete moles are diploid and androgenic in origin, 
with no evidence of fetal tissue. Complete moles usually (75-80%) arise as a consequence of 
duplication of a single sperm following fertilization of an 'empty' ovum. Some complete moles 
(20-25%) can arise after dispermic fertilization of an 'empty' ovum. Partial moles are usually 
(90%) triploid in origin, with two sets of paternal haploid genes and one set of maternal haploid 
genes. Partial moles occur, in almost all cases, following dispermic fertilization of an ovum. Ten 
percent of partial moles represent tetraploid or mosaic conceptions. In a partial mole, there is 
usually evidence of a fetus or fetal red blood cells.(Soper, Mutch et al. 2004) 
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Among the risk factors identified for GTD are Women in young age group less than 15 years 
old and women older than 50 years old, nulliparous women, low socioeconomic background, 
dietary protein and carotene deficiency. While association with previous molar pregnancy with 
risk increased by 20 to 40 times, the overall recurrence rates stands at the range of 5% .(Savage, 
Williams et al. 2009). 
GTD (hydatidiform mole, invasive mole, choriocarcinoma, placental-site trophoblastic tumour) 
is a rare event in the UK, with a calculated incidence of 11714 live births. While a recorded rate 
of 0.2 to 1.5 per 1000 live birth in the Europe and north American region. There is evidence of 
ethnic variation in the incidence of GTD in the UK, with women from Asia having a higher 
incidence compared with non-Asian women (1/387 versus 11752 live births). However, these 
figures may under represent the true incidence of the disease because of problems with reporting, 
particularly in regard to partial moles. (Savage, Williams et al. 2009) 
GTN may develop after a molar pregnancy, a non-molar pregnancy or a live birth. The incidence 
after a live birth is estimated at 1150 000. Because of the rarity of the problem, an average 
consultant obstetrician and gynecologist may deal with only one new case of molar pregnancy 
every second year. (Sebire and Seckl 2008) 
It is now more frequent to diagnose GTD (particularly hydatidiform mole) in the first trimester 
as a result of hCG determinations and/or sonography (particularly transvaginal). Indeed, these 
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two tests (beta subunit hCG and sonography) are invaluable in diagnosis, management, and 
follow-up of GTD tumors. Levels of hCG in urine or serum correspond to the number of viable 
tumor cells. 
The treatment in GTD is based on subtype of the disease, based on clinical examination, HPE 
report of the Product of conception. 
In general the prognosis in majority of patients with any form of GTD remains excellent, most 
patients require only primary treatment for non malignant conditions, however managing 
patients with malignant condition of GTD could pose a challenge for the gynecologists , despite 
the good prognosis and wide range of treatment , it needs long term follow up and careful close 
monitoring of patients for relapse of the disease, an advanced disease could be difficult treat and 
may carry a poor prognosis. 
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2.0 Literature review 
Gestational trophoblastic disease has long history dating back to 400BC, however it was not well 
understood until year 1895 the modem approach for the understanding, diagnosis and treatment 
of the GTD discovered. In recent years the understanding and management of trophoblastic 
disease found a significant improvement in the prognosis of the disease which was previously 
invariably fatal disease. 
Gestational trophoblastic disease is spectrum of disorder which is pregnancy related ranging 
from benign condition such as hydatidiform mole to malignant condition of invasive mole. 
The incidence of GTD varies according to different regions and greatly differ in people with 
different ethnic background, Asian population appear to have higher rates of GTN, Malaysian 
population with an average incidence of 2.8 in 1000 pregnancy which almost triple the incidence 
of European and American counterpart, while similar rates were observed in Singapore ( 1 in 
500), Japan (1 in 294) ,Iran( 1 in 314). (Cheah, Looi et al. 1993, Nirmala, Nor Azlin et al. 2013) 
There are many classifications for GTD, however WHO classification (2003) is the most 
commonly used by many authors. The clas~ification plays an important role in determining the 
mode of treatment and subsequent monitoring. 
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With the development of effective chemotherapy and development of accurate tumor marker in 
the form of human chorionic gonadotrophin for the purpose of diagnosis and monitoring has 
further improved patient outcome. 
GTD (Gestational Trophoblastic Disease) is classified in to 2 main categories which are the 
Benign and Malignant forms, based on WHO (2003) classification (Figure 1). The benign form 
includes complete and partial hydatidiform mole ,this diagnosis is usually made upon the 
histopathological confirmation of the product of conception. 
The malignant form or Gestational trophoblastic Neoplasia consists of choriocarcinoma, 
persistent trophoblastic disease and placental site tumors. Choriocarcinoma is extremely rare. 
The diagnosis of choriocarcinoma is also achieved by histopathological examination of the 
product of conception. Persistent trophoblastic disease is a clinical diagnosis unlike other forms 
of malignant tumors. It is usually a sequel of either partial or a complete mole, when the disease 
is persistent after initial treatment with suction and curettage and requires chemotherapy as an 
additional treatment when the patient is diagnosed as Persistent trophoblastic disease (PTD). 
The disease is identified as persistent during follow up, using the serum hCG level to recognize 
any plateuing or deviation from normal regression pattern and ultrasound assessment of the 
uterus together with assessment of sign and symptoms such as per vaginal bleeding. The PTD is 
diagnosed according to RCOG Criteria for diagnosis of Persistent Trophoblastic Disease (Table 2.o). 
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Figure I: The World Health Organization (WHO) Classification of Gestational Throphoblastic 
Disease (2003) (Altieri, Franceschi et al. 2003) 
Gestational Trophoblastic Disease 
A Range of pregnancy associated tumors 
commonly known as molar pregnancy 
Non Cancerous 
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mole 
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Mole 
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2.1 Etiology and Pathogenesis: 
All Gestational trophoblastic diseases originate from placental source. A complete hydatidiform 
mole arises as a result of fertilization of an empty ovum or ovum without any maternal 
chromosomes by a single sperm which then duplicates its chromosome to form a 46XX which Is 
completely paternal in origin. Rarely the complete hydatidiform mole is 46XY, which happens 
when an empty ovum is fertilized by 2 spermatozoa. 
A.partial hydatidiform mean while are almost always triploid, It is the result from fertilization of 
an normal ovum by two sperms which gives rise to a triploid containing 69 XXY,XXX and 
sometimes XYY. 
The main difference between the partial mole and complete mole is the presence of maternal 
DNA on immunostaining for partial mole with others features including presence of fetal or 
embryonic tissue on histopathological examination. 
Persistent gestational trophoblastic tumour is a locally invasive diease develops approximately in 
15% of the patients following partial or complete hydatidiform mole.(Berkowitz and Goldstein 
1996). The presenting symptoms are irregular vaginal bleeding, enlarged uterine size, large theca 
lutein cyst and occasionally presenting with metastasis to the lungs (80%), liver (4%), vagina (5-
16%) and brain (10%). (Evans Jr, Soper et al. 1995) 
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The term persistent trophoblastic disease is addressed to patients who presents with plateauing or 
rising level of beta hCG even after complete evacuation. The diagnostic criteria of the persistent 
trophoblastic gestational disease according to FIGO 2000 criteria(Ngan 2004) includes a rise in 
hCG levels of 1 0% or greater over two weeks, a plateau more than four values of hCG for at 
least three weeks, serum hCG concentration of more than 20, 000 lUlL for four weeks or more 
' 
raised hCG concentration 6 months post evacuation even if it is decreasing in trend, heavy 
vaginal bleeding or evidence gastrointestinal or intraperitoneal hemorrhage. 
Choriocarcinoma is an extremely rare malignant tumor. It is the most severe form of molar 
disease. The distinct difference with molar disease is the characteristically absence chorionic 
villi. They usually invade myometrium and endometrium, however they tend to have early blood 
borne metastasis. Prolonged vaginal bleeding is the most common symptom(Soper, Mutch et al. 
2004). Due to this any abnonnal vaginal bleeding more than six weeks following any pregnancy 
should be evaluated with beta hCG. The mortality rate is 14 percent for patients who was 
diagnosed with choriocarcinoma following a term pregnancy.(Lok, Ansink et al. 2006). More 
than half of them presented with brain metastasis or placental site tumors.(Feltmate, Genest et al. 
2001). 
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2.2 Risk factors: 
The risk of developing gestational trophoblastic disease is mainly associated with the extremes 
of maternal age. It is the maternal age that appears to be the most significant risk factor 
associated with molar pregnancy. Women who are at increased risk are those younger than 15 
years old and older than 45 years old in particular over the age of 50. (Savage, Williams et al. 
2009).Women who are 40 year old or more have five to ten fold higher risk of developing 
hydatidiform mole , it is estimated that almost one third of pregnant women at age greater than 
50 year old results in molar pregnancy. 
Other risk factors include geographic location and ethnicity, the incidence of gestational 
trophoblastic diease is higher in Asian population. While a recorded rate of 0.2 to 1.5 per 1000 
live birth in the Europe and north American region. There is evidence of ethnic variation in the 
incidence of GTD in the UK, with women from Asia having a higher incidence compared with 
non-Asian women 1/387 versus 1/752 live births. (Savage, Williams et al. 2009). However as 
rare as it sounds in the European population it is more common in Malaysian population with an 
average of 2.8 in 1000 pregnancy almost triple the incidence compared to European and 
American counterpart, while similar rates were observed in Singapore ( 1 in 500), Japan ( 1 in 
294),Iran( 1 in 314) . (Nirmala, Nor Azlin et al. 2013). (Cheah, Looi et al. 1993) 
Other main identified risk factor are previous molar pregnancy, women following one molar 
pregnancy the risk developing of further molar is less than two percent, however following two 
molar pregnancies the risk is increased up to one in six and following a third molar pregnancy 
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the risk may be as high as fifty percent. Apart from this, other factors which appear to be 
increasing risk for molar pregnancy are carotene deficiency diet and low dietary intake of animal 
fat and very rarely family clusters has been associated. The use of oral contraceptive pill is 
associated with an increased risk of GTD with the relative risk of 1.1 to 2.6.(Palmer, Driscoll et 
al. 1999). 
Mean whil~ factors increasing the risk of Persistent Trophoblastic Disease (PTD) are pre-
evacuation hCG level more than 100 000 lUlL, uterine size larger than gestational age, thecal 
lutein cyst larger than 6cm, maternal age more than forty year old, oral contraceptive before hCG 
falls to undetectable levels. (Berkowitz, Goldstein et al. 1981 ).The risk of developing PTD after 
evacuation of a complete hydatidiform mole is as high as 20% compared to partial hydatidiform 
mole which is around 5%.(Bagshawe 1976). 
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Table 1.0: Risk of molar pregnancy compared to number of viable conceptions for women in 
different age groups. 
Age 
13 
14 
15 
20 
25 
30 
35 
40 
45 
50+ 
Percent Partial 
moles of viable 
conceptions 
0.08 
0.07 
0.04 
0.05 
0.09 
0.11 
0.11 
0.18 
0.29 
0.59 
(Savage, Williams et al. 2009) 
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Percent complete 
moles of viable 
conceptions 
0.32 
0.20 
0.21 
0.06 
0.06 
0.05 
0.05 
0.09 
0.75 
16.2 
Overall risk of 
molar pregnancy 
1 in 250 
1 in 370 
1 in 400 
1 in 909 
1 in 666 
1 in 625 
1 in 625 
1 in 370 
1 in 96 
1in6 
2.3 Presentation and Diagnosis: 
The main presenting complaint for GTD is vaginal bleeding up to in 95% of cases with majority 
of them presenting in the frrst trimester, however as a result of early recognition through 
ultrasound and hCG measurement, vaginal bleeding is reported in 84% of patients only 
compared to 30 years ago which was in 95% of them.(Goldstein and Berkowitz 1994).1n rare 
cases the bleeding maybe severe and life threatening (Chun, Braga et al. 1964).Excessive uterine 
enlargement relative to gestational age is one the classic signs of hydatidiform mole, 
approximately 28% of cases are complete hydatidiform mole while less than 10% in partial 
hydatidiform mole.(Ma, Wong et al. 1990) 
Excessive vomiting occurs in about 25% of molar pregnancy (Goldstein and Berkowitz 1982), 
hydatidiform mo!e should be particularly looked for in those presents together with excessive 
uterine size, with high levels of hCG. Pre eclampsia was previously observed in 27% of patients 
with a complete hydatidiform mole, currently it is reported in only 1 in 74 patients with complete 
mole on a first visit.(Goldstein and Berkowitz 1994). 
Hyperthyroidism was seen more commonly in patients with very high hCG levels, it was 
observed in approximately 7% of women with complete hydatidiform mole, in severe cases 
goiter, fme tremor, weight loss were observed (Twiggs 1984). Despite the strong link between 
hCG and total T4(thyroxin) and T3 (tri-iodothyronine) levels , in one study no significant 
correlation was found linking hCG and T4 and T3 (Amir, Osathanondh et al. 1984). 
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Another common presentation is theca luthein ovarian cyst, it is a direct result of ovarian hyper 
stimulation by high level of hCG (Osathanondh, Berkowitz et al. 1986), prominent thecal lutein 
cyst are more than 6 em in size and may be up to 20 em in size. It is found in approximately in 
25% patients with complete mole (Berkowitz and Goldstein 1997), the risk of torsion is 2.3%. 
After evacuation of molar the cyst usually regress spontaneously in within 2 to 4 months. 
Trophoblastic embolization with respiratory distress is very rare currently, in the past it was at 
the range of 2%, patients usually presented with dyspnea, chest pain and tachycardia. Main 
attributing factors of respiratory distress in molar pregnancy are molar tissue embolization, 
cardiovascular complication of thyroid storm, cardiovascular complication of pre eclampsia. 
Respiratory distress usually resolves within 72 hours with cardiopulmonary support, in a very 
rare occasion disseminated intravascular coagulation may develop. 
Patients with partial hydatidiform mole usually do not have prominent clinical features 
characteristics of a complete hydatidiform mole, in a survey of 81 patient with partial mole, none 
of them had theca lutein cyst, hyperemesis or hyperthyroidism, the initial clinical diagnosis was 
incomplete or missed abortion in 91% patients but only 6.2% patients were diagnosed with 
hydatidiform mole (Berkowitz, Goldstein et al. 1985). 
Today the presentation of Hydatidiform mole has changed dramatically over the past decades 
owed to the easy access to health care facility thus rendering patient to present early and high 
detection rates via widespread use of ultrasound and measurement of hCG levels. 
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The diagnosis of Hydatidiform mole and choriocarcinoma is confirmed by histopathological 
examination of the product of conception, however the mainstay of early diagnosis is ultrasound 
examination and hCG level measurements ,The use of ultrasound and hCG gaining wide 
speared popularity due to its non invasive features with minimal adverse effect ,readily available 
and cost effective method thus becoming choice of many institutions and practitioners. 
Ultrasonography is reliable and sensitive method to diagnose Hydatidiform mole, with the 
introduction of high resolution ultrasound scans it has been a major advantage since the reliable 
and accurate diagnosis can be made early in the pregnancy, the positive predictive value of 
ultrasound is as high as 90% (Fine, Bundy et al. 1989). Among the notable ultrasound features 
for complete mole are placental tissue demonstrating the classical snowstorm appearance 
representing a hyperechoic endometrial echo complex with multiple hypoechoic space which 
contains blood between hydropic villi and enlarged uterus while features of partial hydatidiform 
mole includes focal cystic changes of placenta, increase in transverse diameter of gestational sac 
and presence of fetal part or growth restricted fetus with focally hydropic placenta. The 
differential diagnosis of hydatidiform mole is degenerated missed abortion, degenerating fibroid, 
adenomyosis and rarely uterine malignancy. 
The trophoblastic diease is virtually unique in that it produces beta hCG, a specific marker which 
can be measured in urine or blood and reflects the diease precisely. hCG is a glycoprotein 
produced by syncytiotrophoblasts, it is composed of alpha and beta subunit with the beta subunit 
being unique for hCG. In nonnal singleton pregnancy serum hCG level unlikely to be more than 
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200 000 lUlL. Higher than 200 000 IU/L ofhCG is usually suggestive of molar pregnancy. It may 
do so in multiple gestation which may lead to diagnostic difficulities. Levels with partial mole are 
only infrequently above the level for noma! pregnancy in view of that as a diagnostic marker, 
hCG measurement has a limited value. 
Apart from it's role in diagnosing molar pregnancy, beta hCG can be effectively used to assess 
the response of treatment, recurrence or persistence of the disease. 
The diagnosis of persistent trophoblastic disease is made according strict criteria. The RCOG 
guideline recommends that plateuing or rising hCG level as four or more times for at least three 
weeks and rising as two consecutive increases in hCG concentration of 10% after evacuation, 
heavy vaginal bleeding or evidence of gastrointestinal or intraperitoneal hemorrhage, serum hCG 
concentration of 20 000 IU/L or more in four weeks or more after evacuation, raised hCG 
concentration six months after evacuation even when it is decreasing in trend. Any one of this 
criteria is enough to make a diagnosis of persistant trophoblastic disease.(Berkowitz and 
Goldstein 1996) 
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Table 2.0: RCOG Criteria for diagnosis of Persistent Trophoblastic Disease. 
1 Serum beta hCG 2: 20 000 lUlL more than 4 weeks post evacuation 
2. Raised beta hCG six months after evacuation even if still falling levels 
3. Histological diagnosis of choriocarcinoma 
4. Evidence of metastasis m liver, brain, GIT or radiological opacities >2cm on chest 
radiograph 
s. Heavy vaginal bleeding or evidence of gastrointestinal or intra peritoneal hemorrhage 
6. Plateuing or rising hCG level as four or more times for at least three weeks and rising as 
two consecutive increases in hCG concentration of 10% after evacuation 
(Berkowitz and Goldstein 1996) 
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2.4 Staging: 
Staging system for GTN (Gestational Trophoblastic Neoplasia) has undergone many changes 
and improvement over the decades, efforts has been directed to produce an effective anatomical 
and prognostic staging system in order to facilitate the choice of treatment. In 2009 the 
Collaboration between WHO(W orld Health Organization) and FIGO (International Federation of 
Obstetrics and Gynaecology) along with other agencies has produced current anatomical staging 
and prognostic scoring system. 
The prognostic scoring is particularly is helpful in predicting the likelihood of drug resistant and 
to assist in selection of appropriate treatment regime. The staging system is thought to encourage 
the objective comparison of data from various centers (Kohom 2002). 
The FIGO anatomical staging of GTN (2009) (Appendix A) (Committee 2002, FCoG 2009) 
divides the Stages into stage I, II, III and IV. 
In stage 1, the disease is confmed to the uterus and includes all patients with persistently elevated 
hCG levels, stage II disease is defmed when GTN extends outside of the uterus but limited to the 
genital and pelvic structures such as adnexa, vagina and broad ligament. Stage III is when GTN 
extends to the lungs with or without known genital tract or pelvic organ involvement, the 
diagnosis is usually made based on the rising hCG level in the presence of pulmonary lesions 
viewed best by radiography. Stage IV is patients with advanced disease and involvement of the 
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brain, liver and kidneys and gastrointestinal tract. Stage IV patients are in the high risk category 
because they are most likely to be chemotherapy resistant. 
2.5 Treatment: 
Suction and curettage is the treatment of choice for the evacuation of complete molar 
pregnancies (Sebire and Seckl 2008). Sharp curettage is not generally recommended due to the 
risk of uterine perforation and the risk of Asherman's syndrome. Medical termination should be 
avoided when possible; the use oxytocic therapy may be commenced after evacuation is 
complete unless there is significant bleeding prior or during evacuation. There is a theoretical 
concern that oxytocic agents may force trophoblastic tissues into venous space of placental bed 
and disseminating the disease to the lungs. Whenever the evacuation involves a patient with 
large gestation precaution need to taken if in case of massive hemorrhage a laparotomy setup 
should be available for emergency hysterectomy or bilateral internal iliac artery ligation. 
All patient with Rh-negative should receive Anti D immunoglobulin after the completion of the 
evacuation. 
The treatment of Gestational trophoblastic neoplasia ( GTN) is initiated based on the risk 
assessment of a particular patient who has met the criteria set for the diagnosis of GTN (Table2). 
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The WHO & FIGO prognostic scoring system on prognostic factors is used to identify the risk 
group the patient belongs in order to initiate appropriate treatment.(Appendix B).The group of 
patients can be divided in to low risk group and high risk group. 
Among the components of this scoring system is age in which patient who are more than 40 
years old having higher risk , Antecedent pregnancy which highest risk would be for a term 
pregnancy followed by abortion and mole, interval months from index pregnancy in which time 
longer than 4 months to 12 months carrying a risk point ,pre treatment serum hCG with level 
more than 10,000 iu/1 to more than 1 million having a increased risk followed by largest tumor 
size, 3cm or more at risk ,sites of metastasis except for lung carries risk, number of metastases 
and previously failed chemotherapy. A score of 7 or more is considered as high risk and a score 
of less than 7 is considered low risk (Appendix B). 
Most patients who require additional treatment following their initial evacuation fall into low 
risk group. The role of repeat suction in these patients has been controversial. Studies suggesting 
that repeated evacuation in patients with rising or static hCG levels following their initial 
evacuation is rarely curative (van Trammel, Massuger et al. 2005).Based on these data repeated 
evacuation is only recommended if the hCG level is less than 5000 lUlL and tissue is seen in 
uterine cavity on ultrasound examination. 
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2.5.1 Treatment of Low Risk GTN: 
Single agent chemotherapy, Methotrexate (MTX) is treatment of choice for low risk patients, the 
widely used regime is 50mg intramuscular methotrexate on days 1 ,3,5, and 7 along with folinic 
acid on days 2,4,6,and 8 repeated every 2 weeks .Methotrexate is usually well tolerated,it does 
not cause alopecia or significant nausea and vomiting or myelosuppression, most frequent side 
effect are mucositis, pleural inflammation and mild elevation liver function test. Patients who 
develop methotrexate resistant can be switched to Actinomycin D. ·Single agent MTX 
chemotherapy achieved complete remission in 90.2% of patients with stage I GTN AND 68.2% 
in low risk stage II and III GTN (Berkowitz, Goldstein et al. 1986). 
The use of MTX and Actinomycin D as single agent chemotherapy in low risk GTN produced 
similar efficacy according to several studies(Osbome, Filiaci et al. 2011), however MTX has 
gained popularity because of its easy intramuscular administration compared to intravenous 
administration of Actinomycin D and MTX is less toxic and well tolerated compared to 
Actinomycin D ,overall MTX is less toxic, better tolerability and more convenient for patients 
(Kang, Choi et al. 2010). 
The treatment is continued until normalization of serum hCG levels ,Patients are monitored 
with serial serum hCG 1 to 2 weekly to assess the response to treatment ,further 3 more courses 
will be given to ensure eradication of any residual disease after the hCG return to normal level 
( <2IUIL ), the additional chemotherapy given after normalization of serum hCG have reduced 
recurrence rate to less than 5% (Mutch, Soper et al. 1990). 
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Those patient who develop resistance to single agent chemotherapy can be subjected to 
combined or multi agent chemotherapy with either Etoposide, MTX, Actinomycin D, 
Cyclophosphamide and Oncovin (EMA-CO) or the combination of MTX, Actinomycin D, 
Cyclophosphamide (MAC).MAC is preferred to EMA-CO regimen is some centers because of 
the associated risk of secondary tumor ,risk of leukemia (1 %) due to Etoposide in EMA-CO 
regimen (Berkowitz and Goldstein 1996).Actinomycin D can be given in patient with resistance 
to single agent MTX provided their hCG level is <1 00 lUlL at the time of commencement of 
Actinomycin D, if levels are > 100 IU/L either EMA-CO or MAC regime should be considered 
(Ngan, Chan et al. 2006).Approximately 25% patient will require second line chemotherapy due 
to single agent chemotherapy resistance however. the cure rate is as high almost 100%. 
Hysterectomy as a primary treatment is obsolete nowadays, it is no longer an acceptable 
treatment in women with low risk GTN, with the advancement of chemotherapy drugs and easily 
available monitoring tool such as hCG less radical approach is favored these days, additionally 
hysterectomy does not appear to improve the outcome in women with high risk metastatic 
disease (Lurain 201 0) 
2.5.2 Treatment of High Risk GTN: 
Patients with high risk GTN should be treated with primary multi-agent chemotherapy, latest 
data indicates that a cure rate of 85-90% in high risk patients treated using multi-agent 
chemotherapy such as EMACO (Bower, Newlands et al. 1997) (Escobar, Lurain et al. 
2003).Historical data from treatment prior to introduction of multi agent chemotherapy 
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demonstrated that less than one third of high risk patients would be cured with single agent 
therapy (Bagshawe, Dent et al. 1989).Generally EMACO regimen is well tolerated and serious 
life threatening toxicity is rare, the major side effects of EMACO are mucositis, pleuritis, 
alopecia, liver enzyme derangement ,myelosuppression. 
Among the other multi agent chemotherapy includes combination of cyclophospamide, 
hydroxyurea, actinomycin D, MTX, vincristine, melphalan and doxorubicin (CHAMOMA), 
MTX, etoposide, actinomycin D (MEA), Etoposide, MTX, Actinomycin D, Cyclophosphamide 
with Platinum based agent ,Cispaltin (EMA-EP). 
The relapse rate of high risk GTN is around 7 to 1 O%,approximately 17% patients develop 
resistance to multi agent chemotherapy namely EMACO, in this patients second line regimen 
such as EMA-EP can be used. Despite the recurrence disease the five year survival rate is 
approximately 85% .Patients with poorest prognosis are those with liver and brain metastases, 
long tenn survival rate for liver metastases is 27% and 70% for patients with brain metastases 
and for patients with both brain and liver metastases is only 10% . 
Approximately 4% patients have cerebral metastases at the time of diagnosis, Central nervous 
system (CNS) or brain metastases may require multimodality treatment comprising radiotherapy 
with whole brain irradiation, chemotherapy or surgical resection of localized lesion. Generally 
high dose chemotherapy is given to improve the penetration of the drug into the CNS, Multiagent 
chemotheraphy when combined with intrathecal methotrexate administration, has a cure rate of 
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